Literature DB >> 17105956

Effects of postnatal exposure to methamphetamine on the development of the rat retina.

Lorena G Rodrigues1, Pedro Melo, M Carolina Silva, Maria Amélia Tavares.   

Abstract

Since the development of different cell types in the retina occurs at different rates, it is possible that exposure to an exogenous substance may produce effects during one time period, but not during another. This study aims to analyze the effects of methamphetamine (METH) in the growth pattern of an experimental model as well as neurochemical and immunohistochemical parameters of the dopaminergic system of the rat retina. The three development stages chosen in this study are key markers in rat eye development. Rats were given 15 mg/kg body weight per day of METH as subcutaneous injections in 0.9% saline (3 mL/kg weight/day) from the day after birth PND 1 to PND 6, PND 13, and PND 29. Each daily dose was split into two. The control group was injected subcutaneously with saline. Both the schedule and volume for injecting saline in the control group were the same as for the METH-treated group. There were no significant differences in the total number of offspring per litter among treatment groups. All offspring had similar body weight at birth. Analysis of body weight on PND 1, showed that animals treated with METH had similar body weights to control-treated animals and females had smaller weights than males. For growth evolution, only litters with a sex ratio of four males and four females were used. Animals treated with METH had smaller body weights than the control-treated animals for all ages studied (PND 7, 14, and 30). Within the control group at PND 30, a significant difference was found in the body weight of females, which was lower when compared with males. For the postnatal model, 7 deaths occurred for the METH-exposed group. No deaths occurred in the control group in a total of 16 saline-injected litters comprising 186 pups. Although the levels of dopamine (DA) was within normal values for the postnatally exposed METH group when compared with its respective control group at PND 7 and 30, at PND 14 this was not the case: in this experimental group, the level of DA was lower than in the control group for both females and males. Support for this result was not evident from the TH immunoreactivity studies, probably because the methodology lacks the sensitivity to distinguish any mild effects, such as that observed in the postnatal model at PND 14. The level of the DA metabolite 3, 4-dihydroxyphenylacetic acid (DOPAC) remained unaffected at all ages studied, for both females and males. The results obtained in this study support the view that, during the critical periods in which the catecholamines can influence the development of neurones, METH transiently affects the pattern of the dopaminergic system in the developing retina.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17105956     DOI: 10.1196/annals.1369.059

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  4 in total

1.  Toxic effect of methamphetamine on the retina of CD1 mice.

Authors:  Hong Lai; Huiyang Zeng; Cheng Zhang; Lin Wang; Mark O M Tso; Shenghan Lai
Journal:  Curr Eye Res       Date:  2009-09       Impact factor: 2.424

Review 2.  Ocular manifestations of crystal methamphetamine use.

Authors:  Ribhi Hazin; Jean Lud Cadet; Malik Y Kahook; Dunia Saed
Journal:  Neurotox Res       Date:  2009-02-28       Impact factor: 3.911

3.  In vivo long-lasting alterations of central serotonin transporter activity and associated dopamine synthesis after acute repeated administration of methamphetamine.

Authors:  Wen-Sheng Huang; Guann-Juh Chen; Tung-Han Tsai; Chen-Yi Cheng; Chyng-Yann Shiue; Kuo-Hsing Ma; Skye Hsin-Hsien Yeh
Journal:  EJNMMI Res       Date:  2019-09-18       Impact factor: 3.138

Review 4.  The Adverse Effects of Prenatal METH Exposure on the Offspring: A Review.

Authors:  Jia-Hao Li; Jia-Li Liu; Kai-Kai Zhang; Li-Jian Chen; Jing-Tao Xu; Xiao-Li Xie
Journal:  Front Pharmacol       Date:  2021-07-14       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.